3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
31
Neoplasms
17
Multiple Myeloma
9
Thyroid Neoplasms
8
Hematologic Neoplasms
7
Thyroid Carcinoma, Anaplastic
6
Carcinoma, Non-Small-Cell Lung
6
Brain Neoplasms
6
Lymphoma
5
Glioma
5
Colorectal Neoplasms
5
Thyroid Cancer, Papillary
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Neurofibromatosis 1
3
Leukemia, Myeloid, Acute
3
Biliary Tract Neoplasms
3
Astrocytoma
3
Adenocarcinoma, Follicular
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Skin Neoplasms
2
Neurofibroma, Plexiform
2
Neoplasm Metastasis
2
Glioblastoma
2
Gastrointestinal Stromal Tumors
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Interventions
Fluorouracil
4
Oxaliplatin
3
Capecitabine
3
toripalimab
2
dehydroftorafur
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Biopsy
2
tremelimumab
1
trametinib
1
tislelizumab
1
temoporfin
1
sacituzumab govitecan
1
lenvatinib
1
gemcitabine-oxaliplatin regimen
1
durvalumab
1
binimetinib
1
Stents
1
Sorafenib
1
Radiosurgery
1
Hydroxychloroquine
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Cisplatin
1
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Klatskin Tumor
×
trametinib
×
Clear all
NCT02042443
2017-09-12
S1310
National Cancer Institute (NCI)
Phase 2
Completed
53 enrolled
13 charts